Xenon

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Xenon
Accession Number
DB13453
Description
Not Available
Type
Small Molecule
Groups
Experimental
Purchasing individual compounds or compound libraries for your research?
Learn More
Structure
Thumb
Weight
Average: 131.293
Monoisotopic: 131.904154457
Chemical Formula
Xe
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololXenon may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Xenon.
AcemetacinThe risk or severity of hypertension can be increased when Xenon is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xenon.
AlclofenacThe risk or severity of hypertension can be increased when Alclofenac is combined with Xenon.
AlfentanilThe therapeutic efficacy of Xenon can be increased when used in combination with Alfentanil.
AliskirenXenon may decrease the antihypertensive activities of Aliskiren.
AlmotriptanThe risk or severity of hypertension can be increased when Almotriptan is combined with Xenon.
AmbrisentanXenon may decrease the antihypertensive activities of Ambrisentan.
AminophenazoneThe risk or severity of hypertension can be increased when Aminophenazone is combined with Xenon.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

ATC Codes
N01AX15 — Xenon
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous noble gases. These are inorganic non-metallic compounds in which the largest atom is a halogen atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Homogeneous noble gases
Sub Class
Not Available
Direct Parent
Homogeneous noble gases
Alternative Parents
Not Available
Substituents
Homogeneous noble gas
Molecular Framework
Not Available
External Descriptors
monoatomic xenon (CHEBI:49956)

Chemical Identifiers

UNII
3H3U766W84
CAS number
7440-63-3
InChI Key
FHNFHKCVQCLJFQ-UHFFFAOYSA-N
InChI
InChI=1S/Xe
IUPAC Name
xenon
SMILES
[Xe]

References

General References
Not Available
KEGG Compound
C13373
ChemSpider
22427
RxNav
11363
ChEBI
49957
ChEMBL
CHEMBL1236802
PDBe Ligand
XE
Wikipedia
Xenon
PDB Entries
1c10 / 1c1m / 1c3l / 1c62 / 1c65 / 1c68 / 1c6b / 1c6e / 1c6h / 1c6k
show 128 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedOtherAnaesthesia therapy1
4CompletedTreatmentAnaesthetics Gases, Xenon / Anaesthetics Volatile, Sevoflurane / Depth of Anaesthesia / Nausea, Postoperative / Vomiting, Postoperative1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentHemodynamic Stability1
4Not Yet RecruitingDiagnosticCystic Fibrosis (CF)1
4WithdrawnTreatmentLiver Function After Partial Liver Resection1
3CompletedScreeningCoronary Arteries Disease Risk / Elevated Cardiac Risk1
3CompletedTreatmentAnaesthesia / Postoperative Cognitive Functions1
3CompletedTreatmentAnesthetics, Inhalation / Coronary Artery Bypass Grafting (CABG) / Coronary Heart Disease (CHD) / Sevoflurane / Xenon1
3CompletedTreatmentCoronary Artery Bypass Grafting (CABG) / Coronary Artery Disease (CAD) / General Anesthetic Drug Allergy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 23, 2017 14:42 / Updated on June 12, 2020 11:42

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates